MyVisionXTNCT07465289
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
At risk: Primary completion moved 53 days later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 7 → 18 locations
- Minor Primary and study completion pushed from Jan 23, 2031 to Mar 17, 2031
- Eligibility criteria shortened, about 1 word
- Minor Eligibility criteria expanded, about 1 word
- Notable Recruitment opened
- Eligibility criteria expanded, about 14 words
- Trial sites expanded: 0 → 7 locations
- Secondary endpoints: details revised at 6 of 7 entries
- Notable Start date: Jul 27, 2026 to Sep 16, 2026v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
The study is composed of Extended Observation Period(s) and Symptom-driven Cycle(s). Based on their clinical need for treatment, study participants will be able to start the study with either an Extended Observation Period or a Symptom-driven Cycle. A Symptom-driven Cycle will be initiated based on disease worsening and participants will receive rozanolixizumab based on investigator's medical judgement.
Drugs: Rozanolixizumab
Sites
18 sites in 7 countries
China 5, Spain 4, Japan 3, Georgia 2, United States 2, France 1, Poland 1